Literature DB >> 26000726

Drug development for airway diseases: looking forward.

Stephen Holgate1, Alvar Agusti2, Robert M Strieter3, Gary P Anderson4, Robert Fogel5, Elisabeth Bel6, Thomas R Martin5, Theodore F Reiss5.   

Abstract

Advancing drug development for airway diseases beyond the established mechanisms and symptomatic therapies requires redefining the classifications of airway diseases, considering systemic manifestations, developing new tools and encouraging collaborations.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26000726     DOI： 10.1038/nrd4645

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  5 in total

1.  Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.

Authors:  Alvar Agustí; Josep Maria Antó; Charles Auffray; Ferran Barbé; Esther Barreiro; Jordi Dorca; Joan Escarrabill; Rosa Faner; Laura I Furlong; Judith Garcia-Aymerich; Joaquim Gea; Bertil Lindmark; Eduard Monsó; Vicente Plaza; Milo A Puhan; Josep Roca; Juan Ruiz-Manzano; Laura Sampietro-Colom; Ferran Sanz; Luis Serrano; James Sharpe; Oriol Sibila; Edwin K Silverman; Peter J Sterk; Jacob I Sznajder
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

2.  Network analysis in the investigation of chronic respiratory diseases. From basics to application.

Authors:  Diego Diez; Alvar Agustí; Craig E Wheelock
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

Review 3.  Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms?

Authors:  Lowie E G W Vanfleteren; Janwillem W H Kocks; Ian S Stone; Robab Breyer-Kohansal; Timm Greulich; Donato Lacedonia; Roland Buhl; Leonardo M Fabbri; Ian D Pavord; Neil Barnes; Emiel F M Wouters; Alvar Agusti
Journal:  Thorax       Date:  2013-06-22       Impact factor: 9.139

Review 4.  Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection?

Authors:  Emiel F M Wouters; Niki L Reynaert; Mieke A Dentener; Juanita H J Vernooy
Journal:  Proc Am Thorac Soc       Date:  2009-12

Review 5.  Beyond FEV₁ in COPD: a review of patient-reported outcomes and their measurement.

Authors:  Paul Jones; Marc Miravitlles; Thys van der Molen; Karoly Kulich
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-16
  5 in total
  5 in total

Review 1.  Advances in understanding COPD.

Authors:  Gary P Anderson
Journal:  F1000Res       Date:  2016-09-27

2.  COPD: time to improve its taxonomy?

Authors:  Bartolomé R Celli; Alvar Agustí
Journal:  ERJ Open Res       Date:  2018-02-16

3.  Defining the inflammatory signature of human lung explant tissue in the presence and absence of glucocorticoid.

Authors:  Tracy L Rimington; Emily Hodge; Charlotte K Billington; Sangita Bhaker; Binaya K C; Iain Kilty; Scott Jelinsky; Ian P Hall; Ian Sayers
Journal:  F1000Res       Date:  2017-04-11

Review 4.  Stem cell-based Lung-on-Chips: The best of both worlds?

Authors:  Janna C Nawroth; Riccardo Barrile; David Conegliano; Sander van Riet; Pieter S Hiemstra; Remi Villenave
Journal:  Adv Drug Deliv Rev       Date:  2018-07-25       Impact factor: 15.470

5.  Lung function trajectory and biomarkers in the Tasmanian Longitudinal Health Study.

Authors:  Dinh S Bui; Alvar Agusti; Haydn Walters; Caroline Lodge; Jennifer L Perret; Adrian Lowe; Gayan Bowatte; Raisa Cassim; Garun S Hamilton; Peter Frith; Alan James; Paul S Thomas; Debbie Jarvis; Michael J Abramson; Rosa Faner; Shyamali C Dharmage
Journal:  ERJ Open Res       Date:  2021-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.